Fingolimod, a functional antagonist of S1PR1 and approved as an oral drug for treating relapsing forms of multiple sclerosis, has been reported to exhibit anticancer properties by inhibiting the S1PR1 signaling pathways in various types of cancer (54, 55, 56). Here, S1PR1 is linked to multiple sclerosis.